8-K: Organovo Appoints Norman Staskey as President and CFO Following Hess's Retirement

Organovo Holdings, Inc. has appointed Norman Staskey as its new President and Chief Financial Officer, effective December 30, 2024, following the resignation of Tomas Hess.

Summary

• Organovo Holdings, Inc. has appointed Norman Staskey as President, Chief Financial Officer, and Principal Financial Officer, effective December 30, 2024.
• This appointment follows the resignation of Tomas Hess, who retired from his part-time role on December 24, 2024.
• Mr. Staskey will provide his services through Danforth Advisors, LLC, a financial consulting firm, under an existing consulting agreement.
• Mr. Staskey's hourly rate is $450.00.
• The company believes Mr. Staskey's experience, particularly in mergers and acquisitions, will be beneficial given their interest in strategic transactions.
• Mr. Staskey has a background in managing and leading teams, as well as overseeing financial and operational responsibilities in life sciences companies.
• He has served as a Senior Director at Danforth since May 2021 and as CFO of Azitra, Inc. since October 2022.
• The company has full time internal senior finance staff to assure continuity.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the appointment of an experienced executive, but there are some concerns about the part-time nature of the role and the potential for strategic transactions to introduce risk.

Positives

• The appointment of Norman Staskey brings a seasoned executive with significant experience in managing and leading teams, as well as overseeing financial and operational responsibilities of life sciences companies.
• Mr. Staskey's background in mergers and acquisitions is seen as a strong addition to the company's leadership, given their interest in potential strategic transactions.
• The company has full time internal senior finance staff to assure continuity.
• The transition appears to be well-managed with a consulting agreement already in place with Danforth Advisors.

Negatives

• The departure of Tomas Hess, while for retirement, creates a change in leadership at the CFO level.
• The company is relying on a part-time consultant for the CFO role, which may raise concerns about the level of attention the role will receive.

Risks

• The reliance on a part-time CFO could pose challenges if the company's needs increase or if Mr. Staskey's availability is limited.
• The company's interest in strategic transactions could introduce risks associated with mergers and acquisitions.
• The transition in leadership could create some short-term instability.

Future Outlook

The company is interested in potential strategic transactions involving other pharmaceutical companies, and Mr. Staskey's experience in mergers and acquisitions is expected to be beneficial.

Management Comments

• The Company believes that Mr. Staskeys experience will be a strong addition to the Companys leadership, in particular his background in mergers and acquisitions activity given the Companys interest in potential strategic transactions involving other pharmaceutical companies.
• With Danforths assistance, the Company has identified Mr. Staskey as a strong executive to serve as the Companys President, Chief Financial Officer and Principal Financial Officer.

Industry Context

The appointment of a new CFO with M&A experience suggests that Organovo may be positioning itself for strategic partnerships or acquisitions, which is a common trend in the pharmaceutical industry as companies seek to expand their pipelines and market reach.

Comparison to Industry Standards

• Many small to mid-sized biotech companies use consulting firms for CFO services, especially during transitional periods or when they need specific expertise.
• The hourly rate of $450 for a CFO consultant is within the typical range for experienced professionals in the life sciences sector.
• Companies like Azitra, where Mr. Staskey previously served as CFO, are also in the life sciences space, making his experience relevant to Organovo's needs.
• The use of a consulting firm like Danforth is common for companies that need flexible financial expertise without the commitment of a full-time executive.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of a new CFO with M&A experience positively, as it could signal potential growth opportunities.
• Employees may experience some changes in leadership and reporting structures.
• The company's suppliers and creditors may not be significantly impacted by this change.

Next Steps

• Norman Staskey will assume his role as President, CFO, and Principal Financial Officer on December 30, 2024.
• The company will continue to work with Danforth Advisors under the amended consulting agreement.
• The company will continue to explore strategic transactions.

Key Dates

Keywords

Organovo, CFO, Chief Financial Officer, Norman Staskey, Tomas Hess, Danforth Advisors, executive appointment, mergers and acquisitions, financial leadership, life sciences